Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organic growth [14][15][16] - Non-GAAP EPS for Q4 was $0.21 and $0.51 for the full year, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [14][15][16] - Free cash flow for the full year was $38 million, a notable improvement of $26 million year-over-year, with $546 million in cash, cash equivalents, and marketable securities at year-end [15][20] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [17] - Multi-Omix segment delivered record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [18][19] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [9][10] - The company anticipates core revenue growth between 3%-5% for fiscal 2026, with expected adjusted EBITDA margin expansion of 300 basis points [11][21] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [8][10] - The strategic focus includes reinvesting savings into innovation, sales, marketing, and product management, with a commitment to value creation and operational excellence [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and capitalizing on opportunities arising from customer consolidation and outsourcing trends [9][10] - The company is entering fiscal 2026 from a position of strength, with a clear focus on delivering core growth and margin expansion [11][22] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [13] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [11][22] Q&A Session Summary Question: Guidance on growth and market conditions - Management noted that the market is expected to grow at 1%-2%, with a focus on delivering results for the full year despite a challenging first half due to capital expenditure slowdowns and government funding impacts [25][26][28] Question: Update on SMS growth and backlog - Management expressed confidence in mid-single-digit growth for SMS, supported by a strong backlog and new leadership driving commercial initiatives [29][30] Question: Insights on customer bases and macro conditions - Management highlighted strength in the pharma sector, with ongoing clarity around projects, while noting some delays in academic and government spending due to the recent government shutdown [39][40] Question: Expectations for M&A and market growth - The company is focused on tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions, with a bullish outlook for 2026 [70][71] Question: Performance expectations for automated stores - Management indicated that while the automated stores segment is currently experiencing low single-digit growth, investments in R&D are expected to yield positive results in the long term [72][73]

BJ’s Wholesale Club (NYSE:BJ) Q3 2026 Earnings Call November 21, 2025 08:30 AM ET Company ParticipantsLaura Felice - CFOAng Singh - VP FP&ASteven Zaccone - Director of Equity ResearchNone - Unknown Speaker 2Bill Werner - Executive VPNone - Unknown Speaker 1Bob Eddy - Chairman and CEOConference Call ParticipantsRobbie Owens - AnalystMike Baker - Managing Director and Senior Research AnalystKate McShane - AnalystRupesh Parikh - AnalystPeter Benedict - AnalystPedro Gale - AnalystChuck Grom - AnalystOperatorHel ...

Financial Data and Key Metrics Changes - In Q3 2025, total net revenue reached RMB 1.96 billion, reflecting a 23.9% year-over-year increase but a 13.7% decline sequentially from Q2 [6][14] - Income from operations was RMB 331.9 million, down 29.9% year-over-year and 46.4% sequentially, primarily due to higher provisions for credit losses [14] - Net income was RMB 421.2 million, up 12.1% year-over-year but down 20.2% sequentially [14] - The delinquency rates increased, with the 31-60 day delinquency rate rising to 1.85% from 1.16% in Q2 and 1.02% a year ago [7][14] Business Line Data and Key Metrics Changes - The company facilitated and originated RMB 33.64 billion in loans, an 18.7% increase year-over-year but a 13.7% decline sequentially [4][10] - The outstanding loan balance at the end of the quarter was RMB 62.83 billion, up 37.3% from the previous year [10] - Approximately 3.48 million loans were facilitated, representing a 32% increase year-over-year, with an average loan size of RMB 9,654 [10] Market Data and Key Metrics Changes - The active borrower base was approximately 2.44 million, down 14.4% sequentially but up 24.2% year-over-year [10] - The regulatory environment remains stringent, with a focus on consumer protection and responsible lending practices [9] Company Strategy and Development Direction - The company is prioritizing asset quality and risk management over short-term volume expansion, reflecting a strategic shift in response to regulatory pressures [4][9] - There is a commitment to maintaining a compliance-first mindset and adapting to evolving regulatory standards [9][10] - The focus is on cost efficiency and disciplined execution to ensure long-term value preservation [12] Management's Comments on Operating Environment and Future Outlook - Management expects challenges to persist in the coming quarters but remains confident in the company's ability to navigate these with prudence [18] - The outlook for Q4 2025 anticipates total loan facilitation in the range of RMB 21 billion to RMB 23 billion, reflecting a measured pace of origination [17] - Management acknowledges the potential for continued pressure on industry pricing and profitability due to regulatory changes [9][10] Other Important Information - The company repurchased approximately $67.9 million in shares under its buyback program, with about $48 million remaining under the existing plan [16][26] - The balance sheet remains strong, with total assets at RMB 14.69 billion, up 26.4% year-over-year [15] Q&A Session Summary Question: What is the expected take rate for Q4 given the current risk situation? - Management indicated that the new regulatory regime will likely have a material negative impact on volume, margin, and profitability, making it premature to discuss specific take rates [24][25] Question: Is the company considering returning more capital to shareholders? - Management confirmed that capital return remains a key strategy, with ongoing share repurchases and a commitment to maintaining dividends despite industry pressures [26][27] Question: How does management view the regulatory environment going into early 2026? - Management expressed uncertainty about future regulatory actions but emphasized a focus on compliance and consumer protection [32] Question: Can management provide more details on the uptick in delinquencies? - Management acknowledged the increase in delinquencies due to broader economic challenges and indicated that they expect the delinquency rate to continue climbing in the short term [33][34]

BJ’s Wholesale Club (NYSE:BJ) Q3 2026 Earnings Call November 21, 2025 08:30 AM ET Company ParticipantsLaura Felice - CFOAng Singh - VP FP&ASteven Zaccone - Director of Equity ResearchNone - Unknown Speaker 2Bill Werner - Executive VPNone - Unknown Speaker 1Bob Eddy - Chairman and CEOConference Call ParticipantsRobbie Owens - AnalystMike Baker - Managing Director and Senior Research AnalystKate McShane - AnalystRupesh Parikh - AnalystPeter Benedict - AnalystPedro Gale - AnalystChuck Grom - AnalystOperatorHel ...

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4] - The nuclear medical segment has seen growth in volumes and doses sold, leading to increased revenues [9] - The carbon plant is expected to start producing carbon-14, with the first full batch anticipated in January 2026 [8] Market Data and Key Metrics Changes - The acquisition of Renergen is expected to enhance the company's capabilities in the semiconductor gas vertical, with regulatory approvals nearly complete [5] - The company has secured a contract for silicon-28 and aims to fulfill customer orders by 2026 [4] Company Strategy and Development Direction - The company aims to diversify its operations beyond South Africa and expand its radiopharmaceutical footprint globally [70] - Quantum Leap Energy (QLE) plans to secure the nuclear supply chain and has raised $64.3 million via convertible notes to support its initiatives [13][14] - The acquisition of Skyline Builders is part of a strategy to secure critical material supply chains essential for the U.S. and ASP Isotopes [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operational capabilities and customer relationships, emphasizing the positive feedback from customers regarding the enrichment processes [38] - The focus for the next six months includes completing the Renergen acquisition and achieving operational de-risking by the end of Q1 2026 [39][40] - The company is committed to providing further guidance on revenue projections as clarity improves internally [52][53] Other Important Information - The company is planning to begin construction of new plants in various locations, including Iceland, the U.S., and the U.K., during 2026 [29] - The first quantum enrichment plant is producing ytterbium-176, with commercial quantities expected in the first half of 2026 [7] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of the production process and modifications made after customer visits, which improved the customer-supplier relationship [37][38] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Operational de-risking is expected by the end of Q1 2026, focusing on completing phase 1C of the project [39][40] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue recognition for carbon is expected by the end of December, with silicon isotopes anticipated in the first half of 2026 [41][42] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers were pleased with the results of the samples, indicating that the technology works effectively [44][47] Question: Is the $50-$70 million revenue opportunity in 2026 and 2027 still valid? - The company is not changing previous guidance and will provide updates as more clarity is achieved [49][50][52] Question: Can you help us understand the capital commitment in 2026 for new facilities? - Detailed breakdowns of capital commitments and revenue opportunities will be provided in future updates [54][55] Question: Can you discuss the opportunity for LEU Plus? - LEU Plus is a new focus based on customer inquiries, aimed at increasing power density and extending the life of existing nuclear power plants [56][60] Question: Should we model the $3 million revenue from Skyline Builders going forward? - The revenue from Skyline Builders is not expected to continue, as the focus will shift away from construction [64][66]

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31][32] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [31][32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32][33] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4][5] - The nuclear medical segment has seen growth in volumes and doses sold, leading to increased revenues [9] - The carbon plant is expected to start producing carbon-14, with the first full batch anticipated in January 2026 [8] Market Data and Key Metrics Changes - The acquisition of Renergen is expected to enhance the company's capabilities in the semiconductor gas vertical, with regulatory approvals nearly complete [5][6] - The company is expanding its radiopharmaceutical operations globally, with the first purchase in the U.S. announced for East Coast Nuclear in Florida [10] Company Strategy and Development Direction - The company aims to secure supply chains of critical materials essential to the U.S. and ASP Isotopes, with recent acquisitions supporting this strategy [21][22] - Quantum Leap Energy (QLE) plans to produce lithium-7 and lithium-6 isotopes to meet the growing demand in the nuclear industry [15][16] - The company is focused on operational de-risking and plans to complete the Renergen acquisition and IPO of QLE in the near future [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational capabilities and customer relationships, emphasizing the positive feedback from customers regarding the silicon-28 enrichment process [38] - The company anticipates significant revenue opportunities in 2026 and 2027, particularly around ytterbium-176 and silicon-28 [49][50] Other Important Information - The company has raised $64.3 million via convertible notes, bringing pro forma cash on hand to $81.6 million [13] - The company is planning to construct new plants in various locations, including Iceland, the U.S., and the U.K., during 2026 [29][30] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of the production process and modifications made after customer visits, which improved the customer-supplier relationship [37][38] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Operational de-risking is expected by the end of Q1 2026, focusing on completing phase 1C of the project [39][40] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue recognition for carbon is expected by the end of December 2025, with silicon isotopes anticipated in the first half of 2026 [41][42] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers were pleased with the results of the samples, indicating that the technology works effectively [44][47] Question: Can you discuss the revenue opportunity for Ytterbium-176 and Silicon-28? - The company is maintaining previous revenue guidance of $50-$70 million for 2026 and 2027 [49][50] Question: What is the capital commitment for building new facilities in 2026? - Detailed capital commitment information will be provided in future updates [54][55] Question: Can you elaborate on the LEU Plus opportunity? - LEU Plus is a subcategory of HALEU, driven by customer inquiries, aimed at increasing power density and extending the life of nuclear power plants [56][60] Question: Should the $3 million revenue from Skyline Builders be modeled going forward? - The revenue from Skyline Builders is not expected to continue, as the focus will shift to securing the nuclear supply chain [64][66]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $159 million, up 6% year-over-year, and up 4% organically, with full-year revenue at $594 million, reflecting a 4% increase on a reported basis and 3% organic growth [14][15] - Non-GAAP EPS for Q4 was $0.21, and $0.51 for the full year, with adjusted EBITDA margin at 13% for Q4 and 11.2% for the full year, representing an expansion of approximately 230 basis points in Q4 and 310 basis points for the full year [14][15] - Free cash flow for the full year was $38 million, a notable improvement of $26 million year-over-year, with $546 million in cash, cash equivalents, and marketable securities at year-end [15][20] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $86 million for Q4, up 2% reported and flat organically, with a non-GAAP gross margin of 49.3%, up 180 basis points year-over-year [17][18] - Multi-Omix segment delivered record revenue of $73 million in Q4, representing 11% growth on a reported basis and 10% organic growth, driven by a 50% year-over-year increase in sequencing volume [18][19] Market Data and Key Metrics Changes - The macro environment remains volatile, with softer academic and NIH funding impacting growth, particularly in the U.S. market [9][10] - The company anticipates organic revenue growth of 3%-5% for fiscal 2026, with expectations of a decline of approximately 1%-2% in Q1 due to capital expenditure slowdowns and government shutdown impacts [21][60] Company Strategy and Development Direction - The company has implemented the Azenta Business System (ABS) to enhance operational efficiency and accountability, focusing on driving productivity, organic growth, and targeted M&A [8][10] - Strategic priorities include embedding ABS deeper across the organization, optimizing capital deployment, and continuing to deliver core growth and margin expansion [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic uncertainties and highlighted opportunities arising from customers consolidating partners and investing in automation [9][10] - The company is well-positioned for fiscal 2026, with a focus on operational excellence and a strong balance sheet to support growth initiatives [11][22] Other Important Information - The results exclude B Medical Systems, which is treated as discontinued operations, with an additional non-cash loss of $4 million recorded in Q4 [13] - The company plans to host an Investor Day to outline its multi-year growth strategy and capital deployment priorities [11][21] Q&A Session Summary Question: Guidance on growth expectations and market conditions - Management noted that the market is expected to grow at 1-2%, with capital expenditure slowdowns impacting growth, particularly in the U.S. [25][26] Question: Update on SMS growth and backlog - Confidence in mid-single-digit growth for SMS is supported by a strong backlog and recent investments in commercial initiatives [29][30] Question: Insights on macroeconomic trends affecting customer bases - Management highlighted strength in pharma spending, with some projects being put on hold but showing signs of recovery [38][40] Question: Expectations for M&A activity - The company is focused on tuck-in acquisitions to expand its core business, particularly in SRS and automated solutions [69][70]

Financial Data and Key Metrics Changes - In Q3 2025, total net revenue reached RMB 1.96 billion, reflecting a 23.9% year-over-year increase but a 13.7% decline sequentially from Q2 [14][5] - Income from operations was RMB 331.9 million, down 29.9% year-over-year and 46.4% sequentially, primarily due to higher provisions for credit losses [15] - Net income was RMB 421.2 million, up 12.1% year-over-year but down 20.2% sequentially [15] - The delinquency rates increased, with the 31-60 day delinquency rate rising to 1.85% from 1.16% in Q2 and 1.02% a year ago, and the 91-180 day delinquency rate increasing to 3.52% from 2.91% in Q2 [6][15] Business Line Data and Key Metrics Changes - The company facilitated and originated RMB 33.64 billion in loans, an 18.7% increase year-over-year but a 13.7% decline sequentially [4][11] - The outstanding loan balance at the end of the quarter was RMB 62.83 billion, up 37.3% from the previous year [11] - Approximately 3.48 million loans were facilitated, representing a 32% increase year-over-year, with an average loan size of RMB 9,654 [11] Market Data and Key Metrics Changes - The active borrower base was approximately 2.44 million, which is 14.4% lower sequentially but 24.2% higher year-over-year [11] - The regulatory environment remains stringent, with a focus on consumer protection and responsible lending practices, impacting industry pricing and profitability [10][11] Company Strategy and Development Direction - The company is prioritizing asset quality and risk management over near-term volume expansion, reflecting a deliberate moderation in growth pace [4][19] - There is a commitment to maintaining a compliance-first mindset amid evolving regulatory standards, which is seen as a foundation for long-term stability [10][11] - The focus is on cost efficiency and disciplined execution, ensuring that expenses align with the current measured pace of activity [12][13] Management's Comments on Operating Environment and Future Outlook - Management expects challenges to persist in the coming quarters but remains confident in the ability to navigate them with prudence and maintain profitability [19] - The outlook for Q4 2025 anticipates total loan facilitation in the range of RMB 21 billion to RMB 23 billion, reflecting a continued focus on asset quality and credit discipline [18] - The company acknowledges the potential for further increases in delinquency rates due to broader economic conditions but believes that tighter underwriting will lead to better quality vintages over time [35][36] Other Important Information - The company repurchased approximately $67.9 million in shares under its buyback program, with about $48 million remaining under the existing plan [17][26] - The balance sheet remains strong, with total assets at RMB 14.69 billion, up 26.4% year-over-year, and total shareholders' equity at RMB 7.93 billion, up 15% year-over-year [16] Q&A Session Summary Question: What is the expected take rate for Q4 given the current risk situation? - Management indicated that the new regulatory regime will likely have a material negative impact on volume, margin, and profitability, making it premature to discuss specific take rates [24][25] Question: Is the company considering returning more capital to shareholders given lower business volume? - Management confirmed that capital return remains a priority, with ongoing share repurchases and a commitment to maintain dividends despite industry-wide margin pressures [25][26] Question: How does management view the regulatory environment going into early 2026? - Management expressed uncertainty about future regulatory actions but emphasized a focus on compliance and consumer protection, which may lead to a cautious approach in loan origination [28][29] Question: What is the outlook on delinquencies? - Management acknowledged the uptick in delinquencies due to broader economic challenges but expects stabilization within one to two months as tighter underwriting takes effect [30][31][36]

Financial Data and Key Metrics Changes - Net sales for Q3 were approximately $5.2 billion, growing 4.8% year over year [15] - Total comparable club sales increased 1.1% year over year, with merchandise comp sales growing by 1.8% [15][19] - Adjusted earnings per share were $1.16, a decrease of approximately 2% year over year due to a legal settlement [20] - Adjusted EBITDA was down about 2% year over year to $301.4 million, but grew approximately 5% when adjusting for the settlement [19][20] Business Line Data and Key Metrics Changes - Perishables, grocery, and sundries division grew comp sales by 1.8%, with a two-year stack of 6% [5][16] - General merchandise and services division also increased by 1.8% in Q3, with a two-year stack of about 2% [16] - Digital sales grew by 30% year over year and 61% on a two-year stack, now approaching 17% of total sales [10][17] Market Data and Key Metrics Changes - Membership fee income grew by nearly 10% to approximately $126.3 million, driven by strong member counts and a recent fee increase [8][17] - Comp gallons in the gas business grew 2% year over year, significantly outpacing the industry [19] Company Strategy and Development Direction - The company is focused on enhancing member value through improved merchandising, digital convenience, and expansion of physical footprint [25] - A new club opened in Warner Robins, Georgia, and another in Smyrna, Tennessee, both performing above expectations [10][11] - The company plans to open 14 new clubs this year, the most in many years, and aims for 25-30 new clubs in the next two years [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver value despite a challenging macroeconomic environment [13][24] - The company is narrowing its full-year merchandise comp sales guidance to a range of 2%-3% and increasing expected adjusted earnings per share to $4.30-$4.40 [23][24] - Management highlighted the importance of maintaining a focus on member value and long-term growth strategies [25] Other Important Information - The company has launched new own-brand products aimed at providing high quality at lower prices, enhancing member loyalty [9] - A 10% discount for team members was introduced to support them during the holiday season [61] - The company is leveraging AI for improved shopping experiences and operational efficiencies [72][74] Q&A Session Summary Question: Exposure to SNAP program and member behavior across income demographics - Management noted that low-income consumers showed resilience in purchasing habits despite inflation pressures, with stable performance observed [28][30] Question: Long-term sales growth expectations - Management expressed confidence in achieving long-term growth through improved membership, merchandising, and convenience [35][36] Question: Competitive response in new markets - Management indicated strong performance in new clubs and confidence in competing effectively in markets like Dallas [39][40] Question: Inventory positioning for Q4 - Management acknowledged a conservative inventory position that may limit sales upside but supports overall value for members [44][45] Question: Fourth quarter same-store sales assumptions - Management is cautiously optimistic about Q4 performance, with preparations in place for the holiday season [53][54] Question: General merchandise inventory planning for next year - Management indicated that inventory decisions are made based on ongoing clarity regarding tariffs and consumer response [56][57] Question: Sustainability of SG&A per square foot levels - Management emphasized the importance of maintaining efficiency in operations while planning for future investments [83][84]

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4] - The acquisition of Renergen is nearing completion, with all but one regulatory approval received, expected imminently [5] - The first quantum enrichment plant is producing ytterbium-176, with commercial quantities expected in the first half of 2026 [7] Market Data and Key Metrics Changes - The company has secured contracts for silicon-28 and is looking to satisfy all current customer orders in 2026 [4] - The acquisition of Skyline Builders aims to secure supply chains of critical materials essential to the U.S. and ASP Isotopes [21] Company Strategy and Development Direction - The company is focused on expanding its isotope enrichment capabilities and has plans for multiple new production facilities [8][28] - Quantum Leap Energy aims to stabilize the nuclear supply chain and is developing technologies for lithium-7 and HALEU production [12][18] - The company is also investing in radiopharmaceutical operations, with plans to expand into the U.S. market [11][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational progress and customer relationships, emphasizing the importance of completing phase 1C for de-risking projects [39] - The company anticipates significant revenue opportunities in 2026 and 2027, particularly around ytterbium-176 and silicon-28 [49] - Management acknowledged the complexities of the isotope industry and the need for transparency with investors regarding future projections [50][52] Other Important Information - The company is preparing for the IPO of Quantum Leap Energy, with S-1 documentation filed with the SEC [13][27] - The company plans to begin construction of new plants in various locations, including Iceland, the U.S., and the U.K. during 2026 [28] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of starting up the plant and modifications agreed upon with customers, but operations are currently going well [37] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Expected by the end of the first quarter, focusing on completing phase 1C [39] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue from carbon is expected to ship by the end of December, with silicon isotopes expected to generate revenue in 2026 [41] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers are satisfied with the results of the samples, indicating that the technology works [43][47] Question: Is the $50-$70 million revenue opportunity in 2026 and 2027 still valid? - The company is not changing previous guidance and will provide updates as more clarity is achieved [49][53] Question: Can you help us understand the capital commitment in 2026 for new facilities? - Detailed breakdowns will be provided in future updates, but specifics are not available at this time [54][55] Question: Can you talk about the opportunity for LEU Plus? - LEU Plus is a subcategory of HALEU, driven by customer inquiries, and is expected to enhance power density and extend refueling cycles for existing plants [58][60] Question: Should we model the $3 million revenue from Skyline Builders going forward? - This revenue is not expected to continue, as the focus will shift away from construction activities [63]